Baudax Bio, Inc.
BXRXQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.36K
Close$
Share Statistics
| Market cap | $4,359.00 |
|---|---|
| Enterprise Value | $11.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-177.3 |
| Beta | -11.87 |
| Outstanding Shares | 7,993,522 |
Return
| Return on Equity | 69.89% |
|---|---|
| Return on Assets | -34.76% |
| Return on Invested Capital | -998.24% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 34.67 |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -1.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 19, 2026
EPS Estimate
$-280.00
Average shareholder expectationRevenue Estimate
$633,333
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Baudax Bio, Inc.
9 employees
CEO: Geraldine A. Henwood Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or ...